Ipamorelin Dosage: The Saturating Dose, Timing, and Why More Does Not Help

Almost every ipamorelin protocol in circulation uses 200 to 300 micrograms per injection, subcutaneously, one to three times a day. That band is narrow because of a saturating dose effect: past a certain point the pituitary releases much the same growth hormone pulse whether the injection holds 300 micrograms or 900, so the extra material leaves the vial without doing more work. This page covers where those figures came from, how much confidence they deserve, why timing and frequency move the outcome more than the number does, how to turn a milligram label into marks on a syringe, and where the arithmetic goes wrong.

Ipamorelin is a research compound with no approved human indication, and nothing here is medical advice. For mechanism and evidence before the numbers, the ipamorelin guide covers receptor selectivity and what the literature shows, and the CJC-1295 and ipamorelin stack page covers the combination protocols.

Where the 200 to 300 Microgram Figure Comes From

Worth being blunt about this. No published human dose finding programme has mapped ipamorelin against growth hormone output in healthy adults across a range of doses. The clinical development work that was done targeted a gastrointestinal indication rather than growth hormone optimisation, and it did not produce the dose response curve a dosing page would want to quote.

What exists instead is pharmacology borrowed from the wider secretagogue class, where the pattern is consistent: output rises steeply over a low dose range and then flattens. Community protocols settled in the region where responses appeared reliable and stopped there, because increases past it produced no obvious change. Some write ups express the same band as roughly one microgram per kilogram, which lands most adults back inside 200 to 300 micrograms. That is a rule of thumb, not a derived figure.

The honest description: the number is extrapolated, it is stable across sources because everyone copies the same practice rather than testing it, and it survives mainly because nothing suggests going higher achieves more.

The Saturating Dose, and What It Means in Practice

A growth hormone secretagogue does not manufacture growth hormone. It signals somatotroph cells in the anterior pituitary to release what they already hold. Two things cap that release: the size of the readily releasable pool, and somatostatin tone, the braking signal running against secretion at any moment. Once enough receptors are occupied to trigger a full release, more ligand has nothing left to recruit.

That is what people mean by a saturating dose, and the consequence is practical. Once a protocol sits inside that range, the variables that still move total growth hormone exposure across 24 hours are how many pulses you generate and when, not how many micrograms go into each one. Doubling the injection is the one adjustment that reliably does nothing except empty the vial twice as fast.

The caveat: the exact saturation point has not been measured in humans for ipamorelin. The concept is well supported across the secretagogue class. The precise point where the curve flattens is inferred.

Ipamorelin Dosage Chart

These rows describe community practice, presented as research use information rather than instruction. None has been validated in a controlled human trial.

Read down the second column and the point becomes obvious: the dose per injection barely moves while frequency and timing do the work. As a weekly figure, which is what matters when sizing a vial order, the introductory row is about 0.7 to 1.4 mg per week and the three times daily row about 4.2 to 6.3 mg.

Timing: Fasted, and Why Bedtime Wins the Argument

The largest natural growth hormone pulse of the day occurs in the first phase of slow wave sleep, usually within an hour or two of falling asleep. An injection 30 minutes before bed amplifies a pulse that was going to happen anyway rather than forcing one at an arbitrary hour. Hence the near universal advice that if only one injection happens in a day, it should be that one.

The fasted state argument rests on insulin, the main physiological suppressor of growth hormone secretion. A carbohydrate or protein meal shortly before an injection blunts the response you were dosing for, so most protocols ask for a two to three hour gap after eating and roughly 30 to 45 minutes before eating again. Fat matters less, but keeping the whole window clean is simpler than calculating each meal.

Both arguments rest on growth hormone physiology rather than on trials comparing ipamorelin timings against each other. The physiology is solid. The specific claim that a bedtime injection beats a midday one for a given outcome has not been tested the way the confident phrasing online suggests.

Once, Twice, or Three Times a Day

Ipamorelin has a plasma half life of roughly two hours, so each injection produces one pulse and then clears. Frequency, not dose, is the real lever on daily exposure, which is why the chart escalates injections rather than micrograms.

The counterargument is that the growth hormone axis is a feedback system: sustained IGF-1 elevation raises somatostatin tone, so continuous stimulation is not obviously the same as continuous benefit. No human data settles where that trade off sits. In practice the third daily injection is usually limited less by pharmacology than by the difficulty of finding three genuinely low insulin windows in a working day.

Ipamorelin Dosage in mg, and the Conversion Trap

Doses are quoted in micrograms and vials are labelled in milligrams, which is where most errors live. One milligram is one thousand micrograms, so a 200 mcg dose is 0.2 mg and a 5mg vial holds 5,000 mcg: twenty five doses at 200 mcg, or about twelve days at 200 mcg twice daily.

The arithmetic runs in three steps. Concentration is vial milligrams divided by millilitres of bacteriostatic water added. Volume per dose is the dose in milligrams divided by that concentration. Units are that volume times 100 on a standard U-100 insulin syringe.

Worked example. A 5mg vial in 2mL gives 2.5 mg/mL. A 200 mcg dose is 0.2 mg, so 0.2 divided by 2.5 is 0.08 mL, reading as 8 units. That is a tight mark on a U-100 barrel, where a one unit misjudgement is a 12 percent error. The same vial in 5mL gives 1 mg/mL, at which the identical dose reads as 20 units: the same amount of compound, measured in a part of the syringe that forgives a small mistake.

One constraint pulls against buying the biggest vial. Reconstituted peptide is generally treated as good for about 28 to 30 days refrigerated, and a 10mg vial at 200 mcg once daily is fifty days of material. Size the vial to the protocol, not the price per milligram. The reconstitution guide covers sterile technique and storage, and the ipamorelin dosage calculator runs the unit conversion for any vial and water combination.

Cycle Length and the Desensitisation Question

Growth hormone releasing peptides differ in how quickly the receptor stops responding. Hexarelin is the cautionary example: the most potent of the group, and the one where attenuation over a run is most consistently reported, which is why hexarelin protocols are short by design. Ipamorelin sits at the other end, and that lower desensitisation profile is one reason it displaced the older secretagogues in most stacks.

Cycle lengths follow from that. Eight to twelve weeks on with a four week break is the conservative pattern, particularly with a GHRH analog running alongside. Sixteen to twenty continuous weeks appears at lower doses aimed at sleep and recovery. Low dose nightly use with a break every few months is the longevity oriented pattern.

No controlled human study has tracked growth hormone response to ipamorelin over months, so whether and when it fades is unknown. Lower desensitisation than hexarelin is a comparative claim, not a licence to assume none occurs, and a scheduled break costs very little.

Stacking With CJC-1295, and Why That Pairing Dominates

The saturating dose explains why almost every serious ipamorelin protocol eventually adds CJC-1295. Once extra micrograms achieve nothing, the only way to enlarge a pulse is to recruit a second pathway. CJC-1295 is a GHRH analog acting on a different pituitary receptor: it primes and amplifies, ipamorelin triggers release. The combined response is reported to exceed either alone, which is what you would expect from a system that normally uses both signals together.

The combination does not change the ipamorelin number. It stays at 100 to 300 mcg per injection, paired with a comparable CJC-1295 dose, usually in the same syringe. Which version of CJC-1295 matters far more, because the DAC and no DAC forms are dosed on completely different schedules, and the CJC-1295 dosage guide covers that split. For the alternative GHRH pairing, the ipamorelin versus sermorelin comparison explains why the shorter acting option behaves differently, and the muscle growth peptides overview covers where this stack sits against the other options.

Where the Arithmetic Goes Wrong

• Confusing micrograms with milligrams. A thousandfold error, and the most consequential one available. A protocol calling for 200 mcg drawn as 200 mg is not a large dose, it is several vials.
• Reading a U-40 syringe as a U-100. The same physical volume reads 2.5 times differently on the two scales. Check the barrel before the first draw.
• Treating a blend vial as one compound. A combined CJC-1295 and ipamorelin vial lists a total covering both peptides, so treating the whole label mass as ipamorelin overstates the dose drawn.
• Reusing a unit count from a different vial. Twenty units on the last vial is not twenty units on a different strength reconstituted with a different volume. Recalculate each time and write the concentration on the vial.
• Assuming label weight is peptide weight. Lyophilised powder carries residual water and counterions, so actual peptide content typically runs modestly below the label figure.
• Escalating the dose when nothing happens in week two. Above the saturating range that changes cost and nothing else. Adding a pulse or fixing the fasted window has a mechanism behind it.

Frequently Asked Questions

What is the usual ipamorelin dosage per day?

Community protocols usually land between 200 and 600 micrograms a day, which is 200 to 300 micrograms per injection given once, twice or three times. Expressed per week that is roughly 1.4 to 6.3 milligrams, which is the figure worth checking against vial size and the reconstituted shelf life. None of these totals comes from a published human dose finding programme, so they describe practice rather than an established optimum.

Is there a reliable ipamorelin dosage chart?

There are charts, including the one on this page, and they agree with each other because they all describe the same community practice rather than independent evidence. What any honest chart shows is that the dose per injection barely moves between protocols while the number of injections and the timing change a lot. Treat the rows as a description of what people do, not as a validated schedule.

What is the ipamorelin dosage in mg?

A 200 microgram dose is 0.2 mg and a 300 microgram dose is 0.3 mg. Vials are labelled in milligrams, so a 5mg vial holds 5,000 micrograms, which is twenty five doses at 200 mcg. Confusing the two units is a thousandfold error rather than a small one, and it is the single most consequential mistake available in peptide dosing arithmetic.

What is the best ipamorelin dosage and timing?

The most consistently argued timing is 30 minutes before sleep in a fasted state, because the largest natural growth hormone pulse occurs in early slow wave sleep and insulin suppresses that pulse. A morning fasted injection is the usual second, and a pre training injection the usual third. The reasoning comes from growth hormone physiology rather than from trials that compared ipamorelin timings head to head.

What ipamorelin dosage is used for bodybuilding?

The same 200 to 300 micrograms per injection that appears everywhere else, usually two or three times daily and usually alongside a GHRH analog such as CJC-1295. Raising the ipamorelin dose past the saturating range does not raise the growth hormone pulse, so the body composition protocols add pulses or add a second pathway rather than adding micrograms. Ipamorelin is a research compound with no approved human indication and no evidence base for performance outcomes.